ClearBridge Investments, an investment management company, released its “ClearBridge All Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the ...
NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...
Enlaza's War-Lock platform uses covalent-acting protein drugs with non-natural amino acids, enhancing therapeutic windows for safer, effective treatments. The partnership targets autoimmune diseases ...
BOSTON, September 11, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this ...
VX-993 was generally safe and well tolerated at all doses studied in the trial. The overall incidence of adverse events on VX-993 was similar to placebo. The majority of the AEs were mild or moderate ...
The MK2 Focus ST gets a full stealth transformation with a complete alloy wheel refurb and respray. In this video, you’ll see the process from start to finish — sanding, prepping, painting, and the ...
The Envy Core MK2 ($5,995 USD* through December 31, 2025, $6,995 USD* thereafter) builds on the popular Core MK1 and delivers major hardware advances, including a powerful NVIDIA 5060 GPU, a more ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback